No Detail Found!

Mebendazole Inexplicably Reducing the Breast Cancer Cells Viability Preclinically by Incitement Effects with Methotrexate.

Author(s)
Fatima Rizvi Dow International Medical College, Dow University of Health Sciences, Karachi, Pakistan
Syed Mahboob Alam Dow International Medical College, Dow University of Health Sciences, Karachi, Pakistan
Farah Asad Dow International Medical College, Dow University of Health Sciences, Karachi, Pakistan
Hina Shams Dow International Medical College, Dow University of Health Sciences, Karachi, Pakistan
Abstract
Objective: To perform preclinical (in vitro) interventional trial of mebendazole. Methods: This study carried out in Basic Medical Science Institute, JMPC in alliance with PCMD. The total study duration from March 2016 to February 2017. For assessment of cytotoxic incitement effects of mebendazole with methotrexate we used six different dilutions of mebendazole (1.5µM-100µM) both as alone and in combination with methotrexate (0.5µM-100µM). Cytotoxicity was assessed by MTT and trypan blue dye exclusion cytotoxicity assays. We used primarily two breast cancerous cell lines MCF-7 (representative of invasive ductal carcinoma) and MDA-MB-231 (representative of adenocarcinoma). Results: Mebendazole more effectively reducing the % viability of studied cancerous cell lines as combination therapy with methotrexate. The average percentage decrease of % viability of MCF-7 and MDA-MB-231 were -81.3097 and -66.8711 respectively. This combination showed selectivity towards cancerous cell lines as indicated by non-significant (p=0.183) effects on normal breast epithelial cell line (MCF-10). Conclusion: This study demonstrated that combination therapy of mebendazole with standard chemotherapeutic agent methotrexate unveil incitement effects.
Publication Details
Page(s) 101-106
DOI DOI not available
Published Journal: RADS Journal of Pharmacy & Pharmaceutical Sciences, Volume: 6, Issue: 2, Year: 2018

Request the full text from PASTIC

Keywords
MCF-7, MDA-MB-231, MTT, mebendazole, tryptan blue dye exclusion assay.
References
MukhtarE,AdhamiVM,MukhtarH, 2014.Targeting microtubules by natural agents for cancer therapy,Mol Cancer Ther 13 275 -84
ChandrasekaranG,TatraiP,GergelyF, 2015.Hitting the brakes: targeting microtubule motors in cancer,Br J Cancer 113 693 -8
PanicG,DuthalerU,SpeichB,KeiserJ, 2014.Repurposing drugs for the treatment and control of helminth infections,Int J Parasitol Drugs Drug Resist 4 185 -200
StantonRA,GernertKM,NettlesJH,AnejaR., 2011.Drugs that target dynamic microtubules: a new molecular perspective,Med Res Rev 31 443 -81
AleyasinH,KaruppagounderSS,KumarA,SleimanS,BassoM,MaT, 2015.Antihelminthic Benzimidazoles Are Novel HIF Activators That Prevent Oxidative Neuronal Death via Binding to Tubulin, 22 121 -34
DoudicanNA,ByronSA,PollockPM,OrlowSJ., 2013.XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts,Anticancer Drugs 24 181 -8
TanSK,JermakowiczA,MookhtiarAK,NemeroffCB,SchürerSC,AyadNG, 2018.Drug Repositioning in Glioblastoma: A Pathway Perspective,Front Pharmacol 9 218 -37
BaiRY,StaedtkeV,AprhysCM,GalliaGL,RigginsGJ, 2011.Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme,Neuro Oncol 13 974 -82
GrigoriadisA,MackayA,NoelE,WuPJ,NatrajanR,FrankumJ,Reis-FilhoJS,TuttA, 2012.Molecular characterisation of cell line models for triplenegative breast cancers,BMC 13 619 -33
HollidayDL, 2011.Speirs V. Choosing the right cell line for breast cancer research,Breast Cancer Res 13 215 -22
FlorentoL,MatiasR,TuañoE,SantiagoK,Dela CruzF, 2012.Tuazon A. Comparison of Cytotoxic Activity of Anticancer Drugs against Various Human Tumor Cell Lines Using In Vitro CellBased Approach,Int J Biomed Sci 8 76 -80
SliwkaL,WiktorskaK,SuchockiP,MilczarekM,MielczarekS,LubelskaK, 2016.The Comparison of MTT and CVS Assays for the Assessment of Anticancer Agent Interactions,PLoS One 11 e0155772 -
ParameeS,SookkheeS,SakonwasunC,Na TakuathungM,MungkornasawakulP,NimlamoolW, 2018.Anti-cancer effects of Kaempferia parviflora on ovarian cancer SKOV3 cells,BMC Complement Altern Med 18 178 -91
FoucquierJ,GuedjM., 2015.Analysis of drug combinations: current methodological landscape,Pharmacol Res Perspect 3 e00149 -
ReynoldsCP,MaurerBJ, 2005.Evaluating response to antineoplastic drug combinations in tissue culture models,Methods Mol Med 110 173 -83
BadisaRB,Darling-ReedSF,JosephP,CooperwoodJS,LatinwoLM,Goodman CB, 2009.,Selective Cytotoxic Activities of Two Novel Synthetic Drugs on Human Breast Carcinoma MCF-7 Cells. Anticancer Res 29 2993 -6
NygrenP,FryknasM,AgerupB,Larsson R, 2013.Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer,J Cancer Res Clin Oncol 139 2133 -40
CoyneCP,JonesT,Bear R. Gemcitabine-(C4- amide, 2013.-[anti-HER2/neu] Anti-Neoplastic Cytotoxicity in Dual Combination with mebendazole against Chemotherapeutic-Resistant Mammary Adeno-carcinoma,J Clin Exp Oncol 2 100 -9
SpagnuoloPA,HuJ,HurrenR,WangX,GrondaM,SukhaiMA, 2010.The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma,Blood 115 4824 -33
PantziarkaP,BoucheG,MeheusL,SukhatmeV,Sukhatme VP, 2014.Repurposing Drugs in Oncology (ReDO)-mebendazole as an anti-cancer agent,Ecancermedicalscience 8 443 -59
ZhangF,LiY,ZhangH,HuangE,GaoL,LuoW, 2017.Anthelmintic mebendazole enhances cisplatin's effect on suppressing cell proliferation and promotes differentiation of head and neck squamous cell carcinoma (HNSCC),Oncotarget 8 12968 -82
0

Citations

0

Downloads

80

Views